Meeting
2022 ASCO Annual Meeting
A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC Trial).
Authors
Emily Renninson
University Hospitals Bristol and Weston NHS FT, Bristol, United Kingdom
Emily Renninson , Amarnath Challapalli , Emily Foulstone , Alicia Bravo , Alexandra Soundy , Mark Callaway , Alastair Thomson , Constantine Alifrangis , Mehran Afshar , Anna Tran , Balaji Venugopal , Paul White , Emil Cano , Anand Sharma , Amit Bahl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Penile Cancer
Clinical Trial Registration Number
95561634
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS5094)
DOI
10.1200/JCO.2022.40.16_suppl.TPS5094
Abstract #
TPS5094
Poster Bd #
276b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC trial).
First Author: Amit Bahl
Poster
2023 ASCO Genitourinary Cancers Symposium
Activity and tolerability of maintenance avelumab (AVE) immunotherapy after first-line platinum-based polychemotherapy in patients (pts) with locally advanced or metastatic squamous cell penile carcinoma: Initial results of PULSE study.
First Author: Antoine Thiery-Vuillemin
Poster
2024 ASCO Genitourinary Cancers Symposium
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).
First Author: Chiara Mercinelli
Poster
2021 ASCO Annual Meeting
Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: Preliminary results.
First Author: Thierry Alcindor